Status:
COMPLETED
Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial
Lead Sponsor:
Helwan University
Collaborating Sponsors:
Ain Shams University
Fayoum University
Conditions:
Covid19
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The aim of this study is to evaluate the efficacy and safety of Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed. This study is an open-label, rando...
Detailed Description
Aim: To evaluate the efficacy and safety of Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases. Primary objectives: * Evaluating the role of ...
Eligibility Criteria
Inclusion
- This study will include volunteers household contact of COVID 19 confirmed cases who attend the triage clinic in the participating centers. Included persons should be \> 18 years old and below 65 years, without any contraindications for Mefloquine usage.
Exclusion
- • People with history of previous confirmed COVID-19 infection.
- Pregnant and lactating females.
- People with neuropsychiatric disorders: myasthenia gravis, epilepsy, psychotic disorder, schizophrenia, repeated episodes of anxiety, depression.
- People with liver cirrhosis or raised liver enzymes.
- People with arrhythmias or prolonged QT interval on EKG.
- People with a history of Quinidine-Quinine analogs allergy.
Key Trial Info
Start Date :
March 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT04847661
Start Date
March 28 2021
End Date
June 30 2022
Last Update
March 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helwan University
Cairo, Egypt, 11795